Clinical trial
A Prospective, Observational, Multicenter, Post Marketing Surveillance Study to Assess Safety of Durvalumab in Indian Adult Patients With Resectable Non-Small Cell Lung Cancer (NSCLC)
NCT07760519 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Observational, Multicenter, Post Marketing Surveillance Study to Assess Safety of Durvalumab in Indian Adult Patients With Resectable Non-Small Cell Lung Cancer (NSCLC)
- Lead sponsor
- AstraZeneca
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- September 30, 2026
- Completion date
- April 30, 2030
- Enrollment
- 78 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.